Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia (PRIMAL)
A Phase 1, Dose Escalation Study of Plerixafor in Combination With Induction and Consolidation Chemotherapy in Patients With Relapsed Acute Myeloid Leukemia
Sponsor: Acute Leukemia French Association
Terminated
no recruitment on time
Other terminated trials from Acute Leukemia French Association
Other Acute Myeloid Leukemia trials with similar outcome
A PHASE1 clinical study on Acute Myeloid Leukemia, this trial is terminated or withdrawn. The trial is conducted by Acute Leukemia French Association and has accumulated 5 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Acute Leukemia French Association
- French Innovative Leukemia Organisation
- Genzyme, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .